What Does Incyte (INCY) First Patient Dosing Mean For Its Colorectal Cancer Pipeline?

Incyte (NasdaqGS: INCY) and Adagene have started first patient dosing in a Phase 1 trial combining INCA33890 with muzastotug for microsatellite stable colorectal cancer. The early stage study is testing the investigational combination in a colorectal cancer subgroup where current immunotherapy options are limited. The trial expands Incyte's gastrointestinal oncology research footprint through collaboration with Adagene on this new investigational regimen. There is more to assess with Incyte...